Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
about
Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence - a narrative reviewPre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challengesMultipurpose prevention technologies: the future of HIV and STI protectionDivergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) studyDisclosure of pharmacokinetic drug results to understand nonadherencePerceived Advantages and Disadvantages of Using Pre-Exposure Prophylaxis (PrEP) among Sexually Active Black Women: An Exploratory Study.Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in DeliveryRethinking HIV prevention to prepare for oral PrEP implementation for young African womenBeyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV.Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa.Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.HIV pre-exposure prophylaxis for women.Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy.Can a pill prevent HIV? Negotiating the biomedicalisation of HIV prevention.Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey.Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?Vaginal Prostate Specific Antigen (PSA) Is a Useful Biomarker of Semen Exposure Among HIV-Infected Ugandan Women.Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Acceptability and preferences for safer conception HIV prevention strategies: a qualitative study.Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.Women and ARV-based HIV prevention - challenges and opportunities.PrEP Implementation Science: State-of-the-Art and Research Agenda.Women and ARV-based prevention: opportunities and challenges.Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women.Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography.Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study.Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling.Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1 serodiscordant couples in East Africa: a qualitative evaluation study in Uganda.Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence
P2860
Q26778293-BA61FCD2-643B-48AB-AB82-1D421EDF676CQ26825641-FF5141C4-0C47-41CE-AC23-6D576382FBBAQ26827796-30DB1B3B-CA5C-4521-8B93-8409087C38F9Q27300707-69ADB2E8-DAD0-4EE0-A369-33838D16D5AEQ30674432-02F327EE-DA78-4700-AD26-1BB19B394390Q33908319-769083E6-5029-470D-94C8-D7E6E7540BB3Q35541521-64EF768D-839E-4B40-B2EE-DCACFDAA416DQ35875710-13354627-3426-4231-879C-624D6A017EC4Q35875729-D0ABB49A-C909-4554-85F5-538F3B01F4A8Q36144731-6AFAEE97-60CB-4A7A-9652-556A91346297Q36443803-DAB70FB2-BB60-4155-8D6C-326AB4B5DA9DQ36988613-1B27CB59-5BD1-41D0-AE6F-EA5D75A93B51Q37141403-83DE8F31-35F0-40EE-838A-602C8456200DQ37348460-199DB579-E888-4708-BDB9-9ACB7FDF4091Q37352568-95B3BFFD-FC27-4BB8-AD1B-01919B5602C3Q37404649-77524EE2-3732-4E2B-8189-ACB7A4A94B89Q37736062-F4D5055C-0031-4BE7-8630-60724AEFDC38Q38678847-ACFC9EF8-8493-401E-94DC-42B2FCA3A911Q38849514-CFE8ED4A-CF9A-4A4E-A363-D0851171EC0CQ38852654-5C61F6FB-81FE-479C-BEFA-8B33C8F036E9Q38854447-590C7F7F-95F9-4E51-849C-9173E31B50D9Q40062702-15DC6807-13AF-4673-90E6-E707E1C5DE77Q40281007-83755C45-D24A-4C64-ACB4-F6E5879CEB64Q40992145-C8885AED-2818-48AC-95AC-660548381784Q42668432-B3FDD4EF-6E5E-42EF-9410-8725C44E6C97Q42877276-EA4B64BF-3B29-4E2D-9052-F49B9F063791Q43241737-5DCAE26F-5F2E-42C7-A1D0-DB03DBA864BEQ46553256-32892378-4DBD-47E3-8685-7FC1E8981751Q47105640-81413400-DF7B-4E30-AB0F-86912FCDF8F3Q47107885-64E98947-D207-4060-B3A3-4B4F639A9D15Q50114646-4BF3C495-191B-44DA-B508-A1E3AAB37DF9Q52323543-82865EB5-EA72-4230-9E17-907113859B1DQ53837345-CDD9A171-24FA-4605-AD35-90D04736C6CDQ54961974-6B5D2D59-C85E-492C-8C0F-390ADF45B285Q58595713-E6FDF70F-B87A-41E5-B306-BF607E99D9D4
P2860
Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@ast
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@en
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@nl
type
label
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@ast
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@en
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@nl
prefLabel
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@ast
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@en
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@nl
P2093
P2860
P921
P356
P1476
Perspectives on use of oral an ...... in Johannesburg, South Africa.
@en
P2093
Ariane van der Straten
Elizabeth T Montgomery
Ellen Luecke
Miriam Hartmann
Nicole Laborde
VOICE-C Study Team
P2860
P356
10.7448/IAS.17.3.19146
P433
P577
2014-09-08T00:00:00Z